José Á. García-Sáenz

Author

Also Known As

A. Fabi, Beckmann, M.W., Begoña Bermejo de las Heras, Caballero, Rosalía, Ekici, A.B., Fuentes-Rivera, Hugo, Gapstur, Susan M, García-Saenz, José, García-Saenz, José Ángel, García-Sáenz, José A

516

Publications

14K

Citations

H-Index

Concepts

All Affiliations

Hospital Clínico San Carlos Hospital General Universitario Gregorio Marañón Centro de Investigación Biomédica en Red de Cáncer Instituto de Investigación Sanitaria del Hospital Clínico San Carlos GEICAM – Spanish Breast Cancer Group

JÁ

About

José Á. García-Sáenz is an author at Hospital Clínico San Carlos specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	44	4K
2	Health Sciences	12	12	1.2K
3	Public Health	5	5	100
4	Engineering	1	1	12
5	Biomedical Engineering	1	1	12

José Á. García-Sáenz

113

Publications

Citations

H-Index

Page 1

	Year	Citations
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes Nasim Mavaddat, Kyriaki Michailidou, Joe Dennis, The American Journal of Human Genetics	2018	1.1K
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data François‐Clément Bidard, Dieter Peeters, Tanja Fehm, The Lancet Oncology Metastatic Breast CancerBreast OncologyClinical ValidityIndividual Patient DataMedicine	2014	815
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, Journal of Clinical Oncology	2022	626
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena, Journal of Thoracic Oncology MedicineCancer ManagementClinical TrialsRandomized Phase 3Cancer Treatment	2012	339
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial Sibylle Loibl, Frederik Marmé, Miguel Martín, Journal of Clinical Oncology	2021	310
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck Ricardo Hitt, H. Cortés-Funes, Juan J. Grau, Annals of Oncology MedicinePathologyPhase Ii StudyWeekly PaclitaxelFirst-line Treatment	2011	220
Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables Javier Sastre, M.L. Maestro, Javier Puente, Annals of Oncology Tumor BiologyMedicineColorectal CancerPathologyTumor Cells	2008	216
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial Miguel Martín, Monserrat Muñoz, A. Balil, The Lancet Oncology Metastatic Breast CancerOncologyBreast OncologyMedicineBreast Cancer	2007	186

Page 1